atorvastatin xiromed (tinavast) filmuhúðuð tafla 80 mg
medical valley with subfirm xiromed - atorvastatin kalsíum tríhýdrat - filmuhúðuð tafla - 80 mg
atorvastatin xiromed (tinavast) filmuhúðuð tafla 20 mg
medical valley with subfirm xiromed - atorvastatin kalsíum tríhýdrat - filmuhúðuð tafla - 20 mg
atorvastatin xiromed (tinavast) filmuhúðuð tafla 10 mg
medical valley with subfirm xiromed - atorvastatin kalsíum tríhýdrat - filmuhúðuð tafla - 10 mg
atorvastatin xiromed (tinavast) filmuhúðuð tafla 40 mg
medical valley with subfirm xiromed - atorvastatin kalsíum tríhýdrat - filmuhúðuð tafla - 40 mg
rosuvastatin xiromed filmuhúðuð tafla 20 mg
medical valley invest ab - rosuvastatinum kalsíum - filmuhúðuð tafla - 20 mg
rosuvastatin xiromed filmuhúðuð tafla 10 mg
medical valley invest ab - rosuvastatinum kalsíum - filmuhúðuð tafla - 10 mg
rosuvastatin xiromed filmuhúðuð tafla 5 mg
medical valley invest ab - rosuvastatinum kalsíum - filmuhúðuð tafla - 5 mg
rosuvastatin xiromed filmuhúðuð tafla 40 mg
medical valley invest ab - rosuvastatinum kalsíum - filmuhúðuð tafla - 40 mg
arikayce liposomal
insmed netherlands b.v. - amikacin sulfate - sýkingar í öndunarvegi - sýklalyf fyrir almenn nota, - arikayce liposomal is indicated for the treatment of non-tuberculous mycobacterial (ntm) lung infections caused by mycobacterium avium complex (mac) in adults with limited treatment options who do not have cystic fibrosis.
lorviqua
pfizer europe ma eeig - lorlatinib - krabbamein, lungnakrabbamein - antineoplastic agents, protein kinase inhibitors - lorviqua as monotherapy is indicated for the treatment of adult patients with anaplastic lymphoma kinase (alk)‑positive advanced non‑small cell lung cancer (nsclc) previously not treated with an alk inhibitor. lorviqua as monotherapy is indicated for the treatment of adult patients with alk‑positive advanced nsclc whose disease has progressed after:alectinib or ceritinib as the first alk tyrosine kinase inhibitor (tki) therapy; orcrizotinib and at least one other alk tki.